Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Striverdi Respimat olodaterol: Phase III data

A double-blind, crossover, international Phase III trial in 122 patients with COPD showed that once-daily 5 and 10 µg olodaterol delivered via the company's Respimat inhaler each met the co-primary endpoints of improving mean FEV1 AUC from 0-12 hours and

Read the full 408 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers